Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

Interest income and other, net 33,935 411,352 308,973 1,426,386 ------ ------- ------- --------- Net loss $(9,406,247) $(9,188,183) $(32,655,640) $(25,181,525) =========== =========== ============ ============ Basic and diluted net loss per share $(0.28) $(0.31) $(1.01) $(0.89) ====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 33,103,345 29,253,693 32,250,194 28,377,733 ========== ========== ========== ========== Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets September 30, December 31, 2009 2008 ---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $19,240,782 $16,778,880 Short-term investments 23,243,958 22,547,515 Prepaid expenses and other current assets 579,134 744,670 ------- ------- Total current assets 43,063,874 40,071,065 Property and equipment, net 697,328 694,183 Long-term investments 882,000 1,032,000 Other assets 498,644 498,250 ------- ------- Total assets $45,141,846 $42,295,498
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... septembre 2014 Mapi, société créée à ... a été depuis 40 ans l,un des ... traditionnelles par des évaluations recentrées sur le ... impacts économiques des traitements. Logo ... A cours d,une récente conférence téléphonique avec ...
(Date:9/18/2014)... 18, 2014 OMICS Group International ... to participate in the ‘Open Access Week’ by ... OMICS Group Pharma Journals from 20-26th ... the fastest emerging Sciences, accelerating with a tremendous ... across the globe. The industry is gearing with ...
(Date:9/18/2014)... is a group of rare diseases that afflict ... Its onset hits at the fetal stage and ... the gene encoding fibroblast growth factor receptor 3 ... skeletal dysplasia, thanatophoric dysplasia (TD), a skeletal dysplasia ... is often lethal, and achondroplasia (ACH), which causes ...
(Date:9/18/2014)... Artificial sweeteners, promoted as aids to weight loss and ... intolerance and metabolic disease; and they do it in ... of the gut microbiota the substantial population of ... of experiments in mice and humans, were published today ... Eran Elinav of the Weizmann Institute,s Immunology Department, who ...
Breaking Biology Technology:1974 - 2014 - Mapi fête ses 40 ans 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Israel and NEW YORK, October 2 ... on,Company,s Diagnostic and Therapeutic Development Programs, as Well ... (Nasdaq: ROSG ), a global leader in,microRNA-based ... R&D Day on microRNAs and their significant potential ...
... /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), a ... of technologies targeting the chronic inflammation,underlying cardiovascular and ... close of the North American financial markets,on Tuesday, ... web cast will also,be conducted on Tuesday, October ...
... 2 Othera Pharmaceuticals, Inc., a,specialty pharmaceuticals ... oncology, and inflammatory disease, has,announced the appointment ... Chief,Scientific Officer effective immediately. In this position, ... execution of Othera,s research,and clinical development programs. ...
Cached Biology Technology:Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 2Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 3Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007 4Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 2Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 3Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation 4Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 2Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer 3
(Date:9/18/2014)... and their colleagues have built the first smartphone ... performance and behavioral trends. In other words, your ... if you don,t -- and how that affects ... happiness, stress, depression and loneliness to their academic ... population for example, to monitor mental health, ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2Transparent larvae hide opaque eyes behind reflections 2
... can counteract the effects of tumor-promoting molecules in skin ... University of Pennsylvania School of Medicine. Using animal models, ... in epithelial cells, preventing uncontrolled cell growth caused by ... published online in the Journal of Biological Chemistry, suggests ...
... suffering chronic obstructive pulmonary disease (COPD) attempt to ... contradicts the conventional wisdom on the capabilities of ... attempted regional elastic fiber repair in severe emphysema," ... Patterson and Richard Pierce of Washington University, St. ...
... neurons may have been a key factor in why ... primate relatives. In a study comparing the genomes of ... U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley ... high degree of genetic differences in DNA sequences that ...
Cached Biology News:Signal protein shows promise for blocking tumor promoters in skin cells 2Lungs try to repair damaged elastic fibers 2Neuron cell stickiness may hold key to evolution of the human brain 2Neuron cell stickiness may hold key to evolution of the human brain 3Neuron cell stickiness may hold key to evolution of the human brain 4
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Biology Products: